Explore Edwards Lifesciences (NYSE:EW) leading innovations in heart care and its impact on S&P 500 healthcare stocks.

Edwards Lifesciences (EW) stock slips as Oppenheimer downgrades the company to Perform from Outperform citing concerns over two upcoming trial readouts. Read more here.

New innovation marks a major step toward reducing Thailand's healthcare burden as 80% of cardiovascular diseases are preventable.1,2 Edwards Lifesciences (NYSE: EW), the global leader in structural ...

Like her mother, Linda was diagnosed with severe aortic stenosis, also referred to as heart valve failure, a condition in which the aortic valve stiffens due to calcium buildup, making it harder for ...

Edwards Lifesciences is all set to release its fiscal third-quarter earnings later this month, and analysts project a ...

Spire Nottingham Hospital has reached a historic milestone in cardiac surgery, becoming the first private hospital in the ...

17 analysts have expressed a variety of opinions on Edwards Lifesciences (NYSE:EW) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below offers a condensed ...

It’s meant to support the valve guidelines and aid in disentangling the complexities of the tricuspid field, one of the ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Dr Rohit Singh, Senior Director–Medical Affairs, Edwards Lifesciences discusses early diagnosis gaps in aortic stenosis, new ...

Edwards Lifesciences (EW) has seen its stock trend lower over the past month, down about 6%. Investors are keeping an eye on ...

Shares of Edwards Lifesciences Corp. EW shed 1.26% to $75.09 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.13% to ...